Business Updates and First Half 2026 Financial Results

September 21, 2026

ABIVAX

Table of Contents

ABIVAX

Forward Looking Statements

This presentation contains information pertaining to Abivax SA (“Abivax,” the “Company,” “we,” “our” or “us”).

Certain statements included in this presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goals,” “intend,” “likely,” “may,” “might,” “ongoing,” “objective,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “will” and “would” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on the Company’s current strategy, plans, objectives, assumptions, estimates and projections. These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod, the expected timing for completion of the Phase 2b ENHANCE-CD induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, Abivax’s expectations for regulatory approval and commercialization of obefazimod for UC, Abivax’s expectations regarding candidate selection for its IBD combination-therapy program, Abivax’s cash runway, and other statements that are not historical fact. Current results are not necessarily indicative of future results, including any clinical progress updates Abivax may provide from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements are subject to inherent risks, contingencies and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A description of the main risks, contingencies and uncertainties applicable to the Company can be found in the documents filed by the Company with the Autorité des marchés financiers (“AMF”) pursuant to its legal obligations, including the 2026 Universal Registration Document, as amended, available on the AMF website (www.amf-france.org/fr) and the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on March 23, 2026 under the caption “Risk Factors” as well as other filings the Company makes with the SEC from time to time, available on the SEC’s website (www.sec.gov), as well as in the documents that may be published in the future by the Company. These documents are also available on Abivax’s website (www.abivax.com).

If any of these risks materialize or Abivax’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that are presently unknown by the Company or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Abivax’s expectations, plans, or forecasts of future events and views as of the date of this presentation and are qualified in their entirety by reference to the cautionary statements herein. Abivax anticipates that subsequent events and developments will cause the Company’s assessments to change. These forward-looking statements should not be relied upon as representing Abivax’s assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither Abivax nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as required by law.

Ongoing and future clinical development, including our Phase 3 UC and Phase 2b CD clinical programs, trial design and initiation, is subject to assessment of clinical data of obefazimod by European Medicines Agency ("EMA"), U.S. Food and Drug Administration ("FDA") and other regulatory authorities. These authorities could request important modifications to the design of the ongoing and future clinical trials and/or request that additional studies or trials be conducted prior to their initiation. The FDA, EMA or other regulatory authorities may take decisions that would result in a delay or a clinical hold of Abivax’s clinical programs

This presentation also contains alternative performance measures ('APMs') as defined in the ESMA Guidelines on Alternative Performance Measures (ESMA/2015/1415). These include 'cash runway' and 'cash on hand' figures. These APMs are not defined under IFRS and should not be considered as alternatives to IFRS measures. For definitions, reconciliations, and further details, please refer to the Company's half-year financial report available on www.abivax.com.

ABIVAX

An Experienced Leadership Team Positioned to Execute Obefazimod's Next Phase of Development

Marc de Garidel, MBA
Chief Executive Officer

Didier Blondel
Chief Financial Officer & Corporate Secretary

New Executive Appointment

Chris Rabbat, Ph.D.
Chief Medical Officer

Ida Hatoum
Chief People Officer & Chief Compliance Officer

New Executive Appointment



Tim Kelly, MS, MBA
Chief Technical Officer

Pierre Courteille Pharmacist, MBA
Chief Business Officer

Michael Nesrallah, MBA
Chief Commercial Officer



David Zhang Ph.D.
Chief Strategy Officer

Nadege Briancon-Eris, Ph.D.
SVP, Global Head of Development Operations

Maurus de la Rosa, Ph.D.
SVP, Research

Business Updates

Positive Pre-NDA Interaction	Constructive FDA feedback resulted in alignment on the Company's planned NDA submission strategy and **supported the planned content and format** of the NDA submission
On Track for NDA Submission	Abivax remains **on track to submit its first NDA for obefazimod** for Ulcerative Colitis by the **end of 2026**
Significant UEGW Presence	Abivax plans a significant UEGW 2026 presence, including **additional analyses from the Phase 3 maintenance program**
Crohn's Phase 2b Trial Momentum	**Recruitment in the Crohn's disease Phase 2b study is accelerating**, and Abivax remains on track for a topline **induction readout in mid-2027**
Progress on Combination Therapy	Preclinical studies of obefazimod **combinations with α4β7, IL-23, PDE4, and AHR agents** are underway

Additional business updates are planned for early January 2027, ahead of the J.P. Morgan Healthcare Conference

ABIVAX

Strong Financial Position and Extended Cash Runway into Q4 2029

Strong Financial Position

Approximately **€1.2B cash on hand*** as of early July

Extended Cash Runway

Cash runway into **Q4 2029** based on current operating assumptions

Enhanced Financial Flexibility

Royalty certificate repurchase completed in Q2 2026, reducing the royalty overhang and enhancing financial flexibility

*Approximately €402.4 million cash on hand as of June 30, 2026 + €767.1 million in net proceeds from July public offering

ABIVAX

Key Milestones Through Mid-2027

- ☑ **Q3 2025** — **Phase 3 Topline UC Induction Data**
- ☑ **Q2 2026** — **Phase 3 Topline UC Maintenance Data**
- ☐ **End of 2026** — **Expected Obefazimod US FDA NDA Submission**
- ☐ **End of 2026** — **IBD Combo Therapy Candidate Selection**
- ☐ **Mid-2027** — **Phase 2b Topline CD Induction Data**

2025		2026				2027			
Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
★ *Positive Ph 3 topline UC Induction data readout*			★ *Positive Ph 3 UC maintenance data readout (Part 1 & 2)*		★ *US FDA NDA submission expected* ★ *IBD Combo therapy candidate selection*		★ *Ph 2b topline CD induction data readout expected*		

ABIVAX